Aridis shares plunge ~25% as antibody drug fails Phase 3 trial in pneumonia
gorodenkoff Aridis Pharmaceuticals (NASDAQ:ARDS) AR-301 monoclonal antibody therapy failed the primary endpoint in a phase 3 trial to treat ventilator-associated ...
gorodenkoff Aridis Pharmaceuticals (NASDAQ:ARDS) AR-301 monoclonal antibody therapy failed the primary endpoint in a phase 3 trial to treat ventilator-associated ...
gorodenkoff Ipsen (OTCPK:IPSEY) (OTCPK:IPSEF) presented complete data from a Phase 3 trial showing that its drug Onivyde helped improve overall ...
juststock/iStock via Getty Images Oramed Pharmaceutical' (NASDAQ:ORMP) the drug ORMD-0801 failed to meet the primary endpoint of improving blood sugar ...